Secondhand Tobacco Smoke and Cardiovascular Disease

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT04715568
Phase
PHASE4
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Losartan — DRUG
    50 mg tablets taken orally
  • Placebo — DRUG
    Tablets taken orally

Study Details

This is a double-blind randomized placebo-controlled crossover clinical trial of efficacy and safety of an FDA-approved angiotensin receptor blocker (losartan) to improve cardiopulmonary outcomes in individuals with pre-Chronic Obstructive Pulmonary Disease (COPD) due to prolonged exposure to secondhand tobacco smoke.

Key Dates

Start date
Mar 30, 2021
Status verified
Jul 2025
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
100 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Placebo then Losartan
    Placebo tablets will be administered for the first 4 weeks followed by a washout period of 2 weeks. After the washout period has been completed, losartan tablets will be administered for the next 4 weeks.
  • Experimental: Losartan then Placebo
    Losartan tablets will be administered for the first 4 weeks followed by a washout period of 2 weeks. After the washout period has been completed, placebo tablets will be administered for the next 4 weeks.

Primary Outcome Measure

Mean Left Ventricular Ejection Fraction (LVEF) [ Time Frame: Baseline, approximately 1 day ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
San Francisco Veterans' Affairs Medical CenterSan FranciscoCalifornia94121
Mehrdad Arjomandi, MD
415-221-4810

Find similar trials in San Francisco, CA

Related Studies